The known sorafenib-mediated suppression of immune effector cells, in particular the reduction of the CD8+ T cell subset, was not observed in axitinib-treated immune effector cells in this study, which led the authors to the conclusion that axitinib, rather than sorafenib, seems to be the more suitable partner in complex treatment regimens of cancer patients including immunotherapy[5]. This evidence concerns the gene CD8A and cancer.